Similar articles

• Dose-response hyperplasia and neoplasia from feeding N-2-fluorenylacetamide (2-FAA) to BALB/c mice for varying time intervals.

  Haley TJ, Farmer J, Jaques WE, Frith C, Sprowls RW, Schieferstein G. Haley TJ, et al. Proc Soc Exp Biol Med. 1976 Jun;152(2):156-9. doi: 10.3181/00379727-152-39350. Proc Soc Exp Biol Med. 1976. PMID: 935178
• Acute oral toxicity of N-2-fluorenylacetamide (2-FAA) in several strains of mice.

  Haley TJ, Dooley KL, Harmon JR. Haley TJ, et al. Proc Soc Exp Biol Med. 1973 Sep;143(4):1117-9. doi: 10.3181/00379727-143-37481. Proc Soc Exp Biol Med. 1973. PMID: 4743690 No abstract available.
• Dose-response predictability of urinary bladder hyperplasia by N-2-fluorenylacetamide feeding in mice: its modification by sex.

  Haley TJ, Schieferstein G, Jaques WE, Farmer J, Frith C, Sprawls RW. Haley TJ, et al. J Pharm Sci. 1974 Dec;63(12):1946-7. doi: 10.1002/jps.2600631227. J Pharm Sci. 1974. PMID: 4449029 No abstract available.
• Artificial sweeteners as urinary bladder carcinogens.

  Bryan GT, Yoshida O. Bryan GT, et al. Arch Environ Health. 1971 Jul;23(1):6-12. doi: 10.1080/00039896.1971.10665946. Arch Environ Health. 1971. PMID: 4996434 Review. No abstract available.
• The pathogenesis of experimental bladder cancer.

  Bryan GT. Bryan GT. Cancer Res. 1977 Aug;37(8 Pt 2):2813-6. Cancer Res. 1977. PMID: 326392 Review.